Neuroproteomics and Parkinsons disease: Dont forget human samples

Expert Review of Proteomics

Volumn 8, Issue 3, 2011, Pages 291-294

  Licker, Virginie ^a   Burkhard, Pierre R ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

animal models; biomarker; neurodegeneration; Parkinsons disease; proteomics; substantia nigra

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN A2; APOLIPOPROTEIN E; BETA 2 MICROGLOBULIN; BRAIN DERIVED NEUROTROPHIC FACTOR; DJ 1 PROTEIN; HLA DR ANTIGEN; HLA DRB5 ANTIGEN; INTERLEUKIN 8; LEUCINE RICH REPEAT KINASE 2; MEMBRANE PROTEIN; PROTEIN ACMSD; PROTEIN BST1; PROTEIN CCDC62; PROTEIN GAK; PROTEIN LAMP3; PROTEIN STK39; PROTEIN SYT11; TAU PROTEIN; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

CEREBROSPINAL FLUID ANALYSIS; DISEASE COURSE; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NEUROPROTEOMICS; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROGNOSIS; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; EDITORIAL; METABOLISM; METHODOLOGY; NEUROBIOLOGY;

ANIMALIA;

ANIMALS; HUMANS; NEUROBIOLOGY; PARKINSON DISEASE; PROTEOMICS;

EID: 79959449049     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.11.29     Document Type: Review

References (26)

1. Thomas B, Beal MF. Parkinsons disease. Hum. Mol. Genet. 16(R2), 183-194 (2007).
2. Poewe W. Non-motor symptoms in Parkinsons disease. Eur. J. Neurol. 15(Suppl. 1), 14-20 (2008).
3. Marsden CD. Parkinsons disease. Lancet 335(8695), 948-952 (1990).
4. Brundin P, Li J-Y, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinsons disease pathology spread. Nature 9(10), 741-745 (2008).
5. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinsons disease. Trends Neurosci. 30(5), 244-250 (2007). (Pubitemid 46667168)
6. Braak H, Del Tredici K, Rub U et al. Staging of brain pathology related to sporadic Parkinsons disease. Neurobiol. Aging 24(2), 197-211 (2003). (Pubitemid 36007810)
7. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinsons disease-related pathology. Cell Tissue Res. 318, 121-134 (2004 (Pubitemid 39362633)
8. Singleton A, Gwinn-Hardy K. Parkinsons disease and dementia with Lewy bodies: a difference in dose? Lancet 364(9440), 1105-1107 (2004). (Pubitemid 39296587)
9. Polymeropoulos M, Lavedan C, Leroy E et al. Mutation in the a-synuclein gene identified in families with Parkinsons disease. Science 276, 2045-2047 (1997). (Pubitemid 27443610)
10. Schiesling C, Kieper N, Seidel K, Kruger R. Review: familial Parkinsons disease - genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathol. Appl. Neurobiol. 34(3), 255-271 (2008). (Pubitemid 351590874)
11. Clark LN, Wang Y, Karlins E et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 67(10), 1786-1791 (2006). (Pubitemid 44900754)
12. Ozelius LJ, Senthil G, Saunders-Pullman R et al. LRRK2 G2019S as a cause of Parkinsons disease in Ashkenazi Jews. N. Engl. J. Med. 354(4), 424-425 (2006). (Pubitemid 43145083)
13. Wirdefeldt K, Gatz M, Schalling M, Pedersen NL. No evidence for heritability of Parkinson disease in Swedish twins. Neurology 63(2), 305-311 (2004). (Pubitemid 38971131)
14. Lees AJ, Hardy J, Revesz T. Parkinsons disease. Lancet 373(9680), 2055-2066 (2009).
15. Tanner CM. Advances in environmental epidemiology. Mov. Disord. 25(S1), 58-62 (2010).
16. Consortium IPDG. Imputation of sequence variants for identification of genetic risks for Parkinsons disease: a meta-analysis of genome-wide association studies. Lancet 377(9766), 641-649 (2011).
17. Licker V, Kovari E, Hochstrasser DF, Burkhard PR. Proteomics in human Parkinsons disease research. J. Proteomics 73(1), 10-29 (2009).
18. Beal MF. Parkinsons disease: a model dilemma. Nature 466(7310), 8-10 (2010).
19. Potashkin JA, Blume SR, Runkle NK. Limitations of animal models of Parkinsons disease. Parkinsons Dis. 2011, 658083 (2010).
20. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125(Pt 4), 861-870 (2002). (Pubitemid 34279780)
21. Tokuda T, Salem SA, Allsop D et al. Decreased a-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinsons disease. Biochem. Biophys. Res. Commun. 349(1), 162-166 (2006). (Pubitemid 44331776)
22. Mollenhauer B, Cullen V, Kahn I et al. Direct quantification of CSF a-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213(2), 315-325 (2008).
23. Hong Z, Shi M, Chung KA et al. DJ-1 and a-synuclein in human cerebrospinal fluid as biomarkers of Parkinsons disease. Brain 133(Pt 3), 713-726 (2010).
24. Zhang J, Sokal I, Peskind ER et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol. 129(4), 526-529 (2008). (Pubitemid 352029270)
25. Eller M, Williams DR. Biological fluid biomarkers in neurodegenerative parkinsonism. Nat. Rev. Neurol. 5(10), 561-570 (2009).
26. Crecelius A, Gotz A, Arzberger T et al. Assessing quantitative post-mortem changes in the gray matter of the human frontal cortex proteome by 2-D DIGE. Proteomics 8(6), 1276-1291 (2008) (Pubitemid 351462933)